|
To,
Mr. Kunal Banodkar
Sun Pharmaceutical Industries Ltd.
Sun House CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063; Tel: + 91 22 4324 1234/4324
Dear,
Subject: In-Practice Usage and Performance (IPUP) Study of Prohance
In response to your letter, Classic /IPUP/Prohance/ 2023 1st Apr’23 I agree to participate in
the study as outlined by you.
I understand that:
-
You will provide me with a copy of the study plan, CRF and full prescribing information
on Prohance
-
Prohance will be prescribed and purchased as in my routine practice.
- The patients’ identity will not be disclosed in the CRF.
-
I have to report serious adverse events (SAE), if any, immediately to your monitor or to
you in the AE reporting form.
-
You will provide the assistance of a monitor to verify the information in the CRF with
that in the patients’ case papers and reports.
-
You will pay me by cheque a fee of Rs. 5000 (Rs. Five thousand only) per patient, and
accordingly, on receiving the completed CRFs, of these {{$numberOfPatient}} patient’s, as a compensation for
the extra time spent in record keeping. The cheque for fee may be drawn in favor of
“………………………………………………………………………………………………………………………………………………………………..”
My personal details are given below for accuracy of your records.
|
}}){kind=logo}